PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Pioglitazone Hydrochloride And Metformin Hydrochloride, and when can generic versions of Pioglitazone Hydrochloride And Metformin Hydrochloride launch?
Pioglitazone Hydrochloride And Metformin Hydrochloride is a drug marketed by Aurobindo Pharma Ltd, Chartwell Rx, Macleods Pharms Ltd, Mylan, Teva Pharms Usa, and Torrent Pharms Ltd. and is included in six NDAs.
The generic ingredient in PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE is metformin hydrochloride; pioglitazone hydrochloride. There are forty-nine drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; pioglitazone hydrochloride profile page.
Summary for PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 6 |
NDAs: | 6 |
Finished Product Suppliers / Packagers: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 2 |
Clinical Trials: | 155 |
Patent Applications: | 48 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Minnesota | Phase 2 |
Nanjing First Hospital, Nanjing Medical University | Phase 3 |
Affiliated Hospital of Nantong University | Phase 1 |
See all PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE clinical trials